Flare: Using ‘switch sites’ to modulate previously intractable transcription factors

Structural insights into the conformations of transcription factors inspired Third Rock to create Flare, which will deploy its $82 million series A round to advance programs against targets previously deemed undruggable.

Third Rock Ventures’ Abbie Celniker acknowledged some apprehension at the project’s outset, given that many others have tried to create drugs targeting transcription factors beyond the roughly 1% that have historically been considered druggable...